Adasuve (loxapine)
- Region
- 🇪🇺 EU
- Active substance
- loxapine
- Company
- Ferrer Internacional S.A.
- Status
- Authorised
- Therapeutic area
- Schizophrenia; Bipolar Disorder
- EU approval
- Wed 20 Feb 2013
- Application
- EMEA/H/C/002400
- ATC
- N05AH01
- Official record
- www.ema.europa.eu
Indication
Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Regulatory milestones
No milestones recorded in the last year.
Follow Adasuve
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.